Halozyme Therapeutics, Inc. (0J2O.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 05:25PM BST
| Previous close | 39.83 |
| Open | 40.31 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 40.06 - 40.73 |
| 52-week range | 30.09 - 44.71 |
| Volume | |
| Avg. volume | 1,670 |
| Market cap | 65.421M |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | 0.13 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Mahesh Krishnan Elected to Halozyme's Board of Directors
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
- PR Newswire
Halozyme to Report First Quarter 2024 Financial and Operating Results
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of trading.
- PR Newswire
Halozyme to Participate in Upcoming Investor Conferences
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences:
© 2024 Yahoo. All rights reserved.